Ex vivo organotypic cultures for synergistic therapy prioritization identify patient-specific responses to combined MEK and Src inhibition in colorectal cancer.
Gavert N, Zwang Y, Weiser R, Greenberg O, Halperin S, Jacobi O, Mallel G, Sandler O, Berger AJ, Stossel E, Rotin D, Grinshpun A, Kamer I, Bar J, Pines G, Saidian D, Bar I, Golan S, Rosenbaum E, Nadu A, Ben-Ami E, Weitzen R, Nechushtan H, Golan T, Brenner B, Nissan A, Margalit O, Hershkovitz D, Lahat G, Straussman R.
Gavert N, et al. Among authors: greenberg o.
Nat Cancer. 2022 Feb;3(2):219-231. doi: 10.1038/s43018-021-00325-2. Epub 2022 Feb 10.
Nat Cancer. 2022.
PMID: 35145327